EI

281.6

+0.86%↑

SAN

86

+0.73%↑

MRK1

119.4

+0.67%↑

SHL.DE

47.18

+0.66%↑

UCB

251.9

+2.07%↑

EI

281.6

+0.86%↑

SAN

86

+0.73%↑

MRK1

119.4

+0.67%↑

SHL.DE

47.18

+0.66%↑

UCB

251.9

+2.07%↑

EI

281.6

+0.86%↑

SAN

86

+0.73%↑

MRK1

119.4

+0.67%↑

SHL.DE

47.18

+0.66%↑

UCB

251.9

+2.07%↑

EI

281.6

+0.86%↑

SAN

86

+0.73%↑

MRK1

119.4

+0.67%↑

SHL.DE

47.18

+0.66%↑

UCB

251.9

+2.07%↑

EI

281.6

+0.86%↑

SAN

86

+0.73%↑

MRK1

119.4

+0.67%↑

SHL.DE

47.18

+0.66%↑

UCB

251.9

+2.07%↑

Search

Galapagos NV

Open

BrancheGesundheitswesen

31.34 2.89

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

30.36

Max

32.62

Schlüsselkennzahlen

By Trading Economics

Einkommen

48M

-106M

Verkäufe

-9.7M

65M

Gewinnspanne

-161.972

Angestellte

558

Empfehlungen

By TipRanks

Empfehlungen

Sell

12-Monats-Prognose

-15.17% downside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

82M

1.9B

Vorheriger Eröffnungskurs

28.45

Vorheriger Schlusskurs

31.34

Nachrichtenstimmung

By Acuity

44%

56%

130 / 371 Ranking in Healthcare

Galapagos NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Okt. 2025, 23:30 UTC

Heiße Aktien

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2. Okt. 2025, 21:21 UTC

Ergebnisse

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3. Okt. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2. Okt. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2. Okt. 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2. Okt. 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2. Okt. 2025, 22:54 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Scales's JV Buyout Lauded by Bull -- Market Talk

2. Okt. 2025, 22:54 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Forex and Fixed Income Roundup: Market Talk

2. Okt. 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2. Okt. 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Okt. 2025, 21:17 UTC

Akquisitionen, Fusionen, Übernahmen

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2. Okt. 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

2. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Okt. 2025, 20:49 UTC

Akquisitionen, Fusionen, Übernahmen

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2. Okt. 2025, 20:00 UTC

Akquisitionen, Fusionen, Übernahmen

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2. Okt. 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2. Okt. 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2. Okt. 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2. Okt. 2025, 18:45 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2. Okt. 2025, 18:45 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2. Okt. 2025, 18:43 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer-Vergleich

Kursveränderung

Galapagos NV Prognose

Kursziel

By TipRanks

-15.17% Nachteil

12-Monats-Prognose

Durchschnitt 25.38 EUR  -15.17%

Hoch 37 EUR

Tief 19 EUR

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Galapagos NV – Dist angeboten haben.

Rating-Konsens

By TipRanks

Sell

4 ratings

1

Buy

0

Halten

3

Sell

Stimmung

By Acuity

130 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
help-icon Live chat